BioVie Inc (BIVI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.24-3.13%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge BioVie Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Annual ending 2027-06-30
Revenue	—	367.51M
EPS	—	-0.63
Annual ending 2028-06-30
Revenue	—	0
EPS	—	-0.57

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Successful capital raises to fund clinical development	A primary condition in BioVie Inc's published investment case. The stated target is Raise at least $5M in new capital within the next 12 months.	Intact	capital raises fall below $5M or fail to close within 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable and effective management team	The company has stable management and no recent market stress.	Intact	major management departures or instability within 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advancement toward generating revenue	A primary condition in BioVie Inc's published investment case. The stated target is Achieve first revenue generation by FY27 or show clinical progress enabling revenue.	Intact	no revenue or clinical progress by FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	0 / 0
2026-07-25	Unavailable	Unavailable	0 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 0
2026-07-29	Unavailable	Unavailable	1 / 0
2026-07-30	Unavailable	Unavailable	1 / 0
2026-07-31	Unavailable	Unavailable	1 / 0
2026-08-01	Unavailable	Unavailable	1 / 0
2026-08-02	Unavailable	Unavailable	1 / 0
2026-08-03	Unavailable	Unavailable	1 / 0
2026-08-04	Unavailable	Unavailable	1 / 0
2026-08-05	Unavailable	Unavailable	1 / 0
2026-08-06	Unavailable	Unavailable	1 / 0
2026-08-07	Unavailable	Unavailable	1 / 0
2026-08-08	Unavailable	Unavailable	1 / 0
2026-08-09	Unavailable	Unavailable	1 / 0
2026-08-10	Unavailable	Unavailable	1 / 0
2026-08-11	Unavailable	Unavailable	1 / 0
2026-08-12	Unavailable	Unavailable	1 / 0
2026-08-13	Unavailable	Unavailable	1 / 0
2026-08-14	Unavailable	Unavailable	1 / 0
2026-08-15	Unavailable	Unavailable	1 / 0
2026-08-16	Unavailable	Unavailable	1 / 0
2026-08-17	Unavailable	Unavailable	1 / 0
2026-08-18	Unavailable	Unavailable	1 / 0
2026-08-19	Unavailable	Unavailable	1 / 0
2026-08-20	Unavailable	Unavailable	1 / 0
2026-08-21	Unavailable	Unavailable	1 / 0
2026-08-22	Unavailable	Unavailable	1 / 0
2026-08-23	Unavailable	Unavailable	1 / 0
2026-08-24	Unavailable	Unavailable	1 / 0
2026-08-25	Unavailable	Unavailable	1 / 0
2026-08-26	Unavailable	Unavailable	1 / 0
2026-08-27	Unavailable	Unavailable	1 / 0
2026-08-28	Unavailable	Unavailable	1 / 0
2026-08-29	Unavailable	Unavailable	1 / 0
2026-08-30	Unavailable	Unavailable	1 / 0
2026-08-31	Unavailable	Unavailable	1 / 0
2026-09-01	Unavailable	Unavailable	1 / 0
2026-09-02	Unavailable	Unavailable	1 / 0
2026-09-03	Unavailable	Unavailable	1 / 0
2026-09-04	Unavailable	Unavailable	1 / 0
2026-09-05	Unavailable	Unavailable	1 / 0
2026-09-06	Unavailable	Unavailable	1 / 0
2026-09-07	Unavailable	Unavailable	1 / 0
2026-09-08	Unavailable	Unavailable	1 / 0
2026-09-09	Unavailable	Unavailable	1 / 0
2026-09-10	Unavailable	Unavailable	1 / 0
2026-09-11	Unavailable	Unavailable	1 / 0
2026-09-12	Unavailable	Unavailable	1 / 0
2026-09-13	Unavailable	Unavailable	1 / 0
2026-09-14	Unavailable	Unavailable	1 / 0
2026-09-15	Unavailable	Unavailable	1 / 0
2026-09-16	Unavailable	Unavailable	1 / 0
2026-09-17	Unavailable	Unavailable	1 / 0
2026-09-18	Unavailable	Unavailable	1 / 0
2026-09-19	Unavailable	Unavailable	1 / 0
2026-09-20	Unavailable	Unavailable	1 / 0
2026-09-21	Unavailable	Unavailable	1 / 0
2026-09-22	Unavailable	Unavailable	1 / 0
2026-09-23	Unavailable	Unavailable	1 / 0
2026-09-24	Unavailable	Unavailable	1 / 0
2026-09-25	Unavailable	Unavailable	1 / 0
2026-09-26	Unavailable	Unavailable	1 / 0
2026-09-27	Unavailable	Unavailable	1 / 0
2026-09-28	Unavailable	Unavailable	1 / 0
2026-09-29	Unavailable	Unavailable	1 / 0
2026-09-30	Unavailable	Unavailable	1 / 0
2026-10-01	Unavailable	Unavailable	1 / 0
2026-10-02	Unavailable	Unavailable	1 / 0
2026-10-03	Unavailable	Unavailable	1 / 0
2026-10-04	Unavailable	Unavailable	1 / 0
2026-10-05	Unavailable	Unavailable	1 / 0
2026-10-06	Unavailable	Unavailable	1 / 0
2026-10-07	Unavailable	Unavailable	1 / 0
2026-10-08	Unavailable	Unavailable	1 / 0
2026-10-09	Unavailable	Unavailable	1 / 0
2026-10-10	Unavailable	Unavailable	1 / 0
2026-10-11	Unavailable	Unavailable	1 / 0
2026-10-12	Unavailable	Unavailable	1 / 0
2026-10-13	Unavailable	Unavailable	1 / 0
2026-10-14	Unavailable	Unavailable	1 / 0
2026-10-15	Unavailable	Unavailable	1 / 0
2026-10-16	Unavailable	Unavailable	1 / 0
2026-10-17	Unavailable	Unavailable	1 / 0
2026-10-18	Unavailable	Unavailable	1 / 0
2026-10-19	Unavailable	Unavailable	1 / 0
2026-10-20	Unavailable	Unavailable	1 / 0
2026-10-21	Unavailable	Unavailable	1 / 0
2026-10-22	Unavailable	Unavailable	1 / 0
2026-10-23	Unavailable	Unavailable	1 / 0
2026-10-24	Unavailable	Unavailable	1 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-06-01	1	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Successful capital raises to fund clinical developmentDirect metric needs a verified mapping
Stable and effective management teamDirect metric needs a verified mapping
Advancement toward generating revenueDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

4.4%Typical daily move · historical

Downside history

-57.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BioVie Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The thesis remains at a watch stage: management has reported promising Phase 2 results, but the evidence snapshot gives no revenue or profit data to show commercial progress.

What's priced into BioVie Inc

The snapshot provides no valuation or market-expectations data, so whether BIVI looks cheap or expensive versus peers, or how much clinical success is already assumed, cannot be assessed. The business is loss-making, which makes valuation especially hard to judge from the available evidence.

What the fundamentals likely do

In the near term, earnings risk is elevated, with a history of recent misses and weaker performance than its industry cohort. For the multi-year thesis, the key fundamental evidence is the Phase 2 SUNRISE-PD report: bezisterim improved clinical symptoms and biomarkers, with statistically significant composite endpoint improvements; further development remains to be demonstrated.

What BioVie Inc hinges on

The thesis hinges on whether the Parkinson’s results can be confirmed and translated into further clinical progress. Near-term sector conditions may also matter: stronger results from healthcare bellwethers could support the sector backdrop, while misses or weaker guidance could remove that tailwind. A weakening jobs trend adds another risk flagged in the evidence.